Comparative Pharmacology
Head-to-head clinical analysis: CYCLAPEN W versus PROBAMPACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAPEN W versus PROBAMPACIN.
CYCLAPEN-W vs PROBAMPACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has a similar spectrum to ampicillin but with increased acid stability and oral absorption.
PROBAMPACIN is a synthetic aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and preventing translocation of peptidyl-tRNA from the A-site to the P-site.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
100 mg IV every 12 hours over 30 minutes.
None Documented
None Documented
0.5-1 hour in adults with normal renal function; prolonged to 2-6 hours in renal impairment.
4.5 hours (prolonged to 12-18 hours in severe renal impairment)
Primarily renal (90-100% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic